Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Race/Ethnicity Data Categories Should Use Global Definitions – PhRMA

Executive Summary

FDA should use global definitions to set categories for collection of race and ethnicity data in clinical trials, the Pharmaceutical Research & Manufacturers of America said

You may also be interested in...



FDA Race/Ethnicity Data Guide Retains OMB Terms Despite Industry Criticism

FDA's final guidance for collecting and reporting race and ethnicity data in clinical trials retains Office of Management & Budget definitions despite industry concerns about applying the categories abroad

FDA Race/Ethnicity Data Guide Retains OMB Terms Despite Industry Criticism

FDA's final guidance for collecting and reporting race and ethnicity data in clinical trials retains Office of Management & Budget definitions despite industry concerns about applying the categories abroad

FDA May Revise MedWatch Reporting Methods For Race, Ethnicity Data

FDA is considering revising the way patient race and ethnicity data are collected on MedWatch adverse event reporting forms

Related Content

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel